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Abstract
Background: Single nucleotide polymorphisms in the APOA5-A4-C3-A1 gene complex are associated with elevated plasma
triglycerides and elevated vascular risk in healthy populations. In patients with clinically manifest vascular disease,
hypertriglyceridemia and metabolic syndrome are frequently present, but the contribution of these single nucleotide
polymorphisms to plasma triglycerides, effect modification by obesity and risk of recurrent vascular events is unknown in
these patients.
Methods: Prospective cohort study of 5547 patients with vascular disease. Rs964184 (APOA5-A4-C3-A1 gene complex) was
genotyped, and we evaluated the relation with plasma lipid levels, presence of metabolic syndrome and the risk for new
vascular events.
Results: The minor allele of rs964184 was strongly associated with log plasma triglycerides (b 0.12; 95%CI 0.10-0.15,
p=1.1*10
219), and was also associated with 0.03 mmol/L lower high-density lipoprotein-cholesterol (95%CI 0.01–0.04), and
0.14 mmol/L higher non-high-density lipoprotein-cholesterol (95%CI 0.09–0.20). The minor allele frequency increased from
10.9% in patients with plasma triglycerides ,1 mmol/L to 24.6% in patients with plasma triglycerides between 4 and 10
mmol/L. The relation between rs964184 and plasma triglycerides was modified by body mass index in patients with one
minor allele (b 0.02; (95%CI 20.04–0.09) if body mass index ,24 kg/m2, b 0.17 (95%CI 0.12–0.22) if body mass index .27
kg/m2, p for interaction=0.02). The prevalence of the metabolic syndrome increased from 52% for patients with two copies
of the major allele to 62% for patients with two copies of the minor allele (p=0.01). Rs964184 was not related with recurrent
vascular events (HR 0.99; 95%CI 0.86–1.13).
Conclusion: The single nucleotide polymorphism rs964184 (APOA5-A4-C3-A1) is associated with elevated plasma
triglycerides concentrations in patients with clinically manifest vascular disease. In carriers of one minor allele, the effect on
plasma triglycerides was modified by body mass index. There is no relation between rs964184 and recurrent vascular events
in these patients.
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Introduction
High plasma triglyceride (TG) levels and low high-density
lipoprotein-cholesterol (HDL-c) levels are common among
patients with vascular disease and may contribute to residual risk
after treatment of other risk factors [1,2]. Both genetic and
environmental factors independently influence the plasma TG
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factors together lead to elevated TG levels [4]. Genome-wide
association studies (GWAS) have identified multiple single
nucleotide polymorphisms (SNPs) associated with plasma TG
levels [5–9]. Of these SNPs, rs964184(APOA5-A4-C3-A1) was
also related with the presence of coronary artery disease in a large
GWAS for coronary artery disease [10], although very recently
also rs2954029(TRIB1) and rs264(LPL) were identified in a
GWAS for coronary artery disease [11]. Rs964184 (exact
chromosomal position: 11q23.3:116648917) is located near the
APOA5-A4-C3-A1 gene complex (MIM 606368, MIM 107690,
MIM 107720, MIM 107680), a region with several polymor-
phisms strongly associated with plasma TG levels [5,7–9]. The
nearest gene is ZNF259 (zinc finger protein 259, MIM 603901),
located 359 basepairs 39 from rs964184.
GWAS do not consider effect modification between metabolic
factors and SNPs. However, this may be relevant for SNPs
associated with plasma TG, since the effect of other SNPs in the
APOA5-A4-C3-A1 gene cluster has been shown to depend on
secondary factors such as obesity and alcohol [12,13]. Interactions
between genotype and a second factor could be important to
determine the individual metabolic consequences of obesity.
Overweight and obesity, the metabolic syndrome and the
consequent hypertriglyceridemia are common in patients with
clinically manifest vascular disease [14]. Therefore, the effect of
rs964184 may be different in this population, in which genetically
elevated plasma TG are of clinical interest. Furthermore, it is
unclear whether a small increase in plasma TG has any effect on
the risk for recurrent vascular events in these patients, since all
patients with clinically manifest vascular disease are already at
high risk for recurrent events and are treated accordingly.
In the present cohort study, we investigated the association
between rs964184 and plasma TG levels in patients with vascular
disease and whether this association was modified by body mass
index. Furthermore, we evaluated the association between
rs964184 and clinical parameters such as the metabolic syndrome
and being at treatment lipid targets, as well as the risk for
occurrence of new vascular events.
Methods
Ethics Statement
All patients gave written informed consent, and the Institutional
Review Board of the University Medical Center Utrecht approved
the study.
Patients
Data were used from the Second Manifestations of ARTerial
disease (SMART) cohort, a prospective, ongoing cohort study,
designed to establish the presence of concomitant arterial diseases
and risk factors for atherosclerosis in patients with known arterial
disease or a cardiovascular risk factor. Patients newly referred to
the University Medical Center Utrecht with known arterial disease
or cardiovascular risk factors (hyperlipidemia, hypertension or
diabetes) are eligible for inclusion. After informed consent, patients
underwent a vascular screening protocol including a health
questionnaire, laboratory measurements and physical examina-
tion. A detailed description of this study has been published
previously [15].
For the present study, we used data of 5547 patients, enrolled in
the SMART study between September 1996 and March 2011,
with either a history or recent diagnosis of clinically manifest
arterial disease: coronary artery disease (CAD) (n=3348),
cerebrovascular disease (n=1597), peripheral artery disease
(n=1115) and/or aneurysm of the abdominal aorta (AAA)
(n=495). Patients could be classified into more than 1 disease
category. Patients with plasma TG $10 mmol/L (n=15) were
excluded since this most likely results from a rare genetic cause.
Follow-up
Follow-up duration was defined as the period between study
inclusion and first cardiovascular event or death from any cause,
date of loss to follow-up or the preselected date of 1 March 2011.
During follow-up, all study participants received a questionnaire
every 6 months to obtain information about hospitalizations and
outpatient clinic visits. If a participant reported a possible event, all
available relevant data were collected. Death of a participant was
reported by relatives, the general practitioner or the specialist who
treated the participant, after which all available relevant data were
collected regarding the cause of death. All events were classified
independently by three members of the SMART Study Endpoint
Committee, comprising physicians from different departments.
Outcomes of interest for this study were vascular death,
myocardial infarction and a composite of myocardial infarction,
ischemic stroke and vascular death.
Laboratory assessment
Baseline lipid levels were obtained from fasting patients. Plasma
total cholesterol and TG were measured using commercial
enzymatic dry chemistry kits (Johnson and Johnson). HDL-c in
plasma was determined using a commercial enzymatic kit
(Boehringer-Mannheim) after precipitation of LDL-c and
VLDL-c with sodium phosphotungstate magnesium chloride.
LDL-c was calculated using the Friedewald formula.
Genotyping
Wet-lab genotyping genotyping for SNP analysis was carried
out by KBiosciences, Hertfordshire, UK (www.kbioscience.co.uk),
whose personnel were blinded to patient status, using their
proprietary KASPar PCR technique and Taqman Genotype
calling was carried out using an automated system, the results of
which were checked manually by study personnel using
SNPviewer software. Individuals with a low overall genotyping
rate were removed from the study (n=73). Rs964184 was used for
the present study, for 112 patients (2.0%), rs964184 genotype was
missing, resulting in 5547 patients for the current analyses.
Data analyses
Linear regression models were used to evaluate the association
between rs964184 and several lipid parameters (plasma triglycer-
ides, HDL-c, nonHDL-c, apoB), with adjustment for age and sex.
Since mainly nonHDL-c and apoB are affected by lipid-lowering
therapy, these analyses were also adjusted for lipid-lowering
medication. ApoB was only available for patients included from
2006 onwards (2133 patients). Furthermore, to investigate whether
the association between rs964184 and plasma TG is modified by
metabolic consequences of obesity, we included an interaction
term with body mass index in a separate model.
To determine whether rs964184 is associated with metabolic
syndrome prevalence, we used a logistic regression model, adjusted
for age and sex. Additionally, in patients using lipid-lowering
medication, a logistic regression model adjusted for age and sex
was used to evaluate whether rs964184 is associated with the
proportion of patients who were on treatment target for LDL-c
(2.5 mmol/L), nonHDL-c (3.3 mmol/L) or apoB (100 mg/dL)
[16].
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of rs964184 on vascular events in patients with known vascular
disease, after testing the proportional hazards assumption. This
model was adjusted for age and sex. Furthermore, in a second
model additional adjustment for plasma TG was performed, to
identify whether a possible association between rs964184 and
vascular events could be explained by plasma TG level.
For the analyses, the open source software package R 2.13 was
used. A p-value of ,0.05 was considered statistically significant for
all analyses.
Results
Baseline characteristics
Baseline characteristics according to rs964184(APOA5-A4-C3-
A1) genotype are shown in Table 1. Plasma TG levels are higher
and HDL-c levels are lower for the heterozygotes and the
homozygotes for the G allele. Furthermore, coronary artery
disease is slightly more present in carriers of the G allele, whereas
cerebrovascular disease is slightly less present. The overall minor
allele frequency was 14.2%.
In figure 1 it is shown that the minor allele frequency increases
with increasing levels of plasma TG, being 10.9% in patients with
plasma TG levels between 0 and 1 mmol/L and 24.6% in patients
with plasma TG levels between 4 and 10 mmol/L.
Relation between rs964184 and plasma lipids
Rs964184 was strongly associated with plasma TG levels, with
log(TG) being 0.12 (95%CI 0.10-0.15, p=1.1*10
219) higher per
minor allele (Table 2). The association with HDL-cholesterol was
less strong, HDL-c levels were 0.03 (95%CI 20.04– 20.01)
mmol/L lower per minor allele. The SNP was also associated with
increased levels of nonHDL-c (0.14 mmol/L; 95%CI 0.09 – 0.20)
and apoB (0.03 g/L, 95% CI 0.01 – 0.05).
Table 1. Baseline characteristics stratified per rs964184 genotype.
CC CG GG
(n=4100) (n=1313) (n=134)
Age (years) 60.0 6 10.4 60.1 6 10.3 61.0 6 9.7
Male sex, n (%) 3048 (74) 982 (75) 101 (75)
BMI (kg/m
2)2 6 . 8 6 3.9 26.7 6 4.0 27.1 6 4.0
Total cholesterol (mmol/L) 4.9 6 1.2 5.0 6 1.3 5.2 6 1.3
Triglycerides (mmol/L) 1.6 6 1.0 1.9 6 1.2 2.2 6 1.3
LDL-c (mmol/L) 3.0 6 1.0 2.9 6 1.1 3.0 6 1.1
HDL-c (mmol/L) 1.23 6 0.37 1.20 6 0.35 1.19 6 0.31
Systolic blood pressure (mmHg) 141 6 21 141 6 21 141 6 21
Diastolic blood pressure (mmHg) 82 6 11 82 6 11 81 6 11
Metabolic Syndrome, n (%) 2139 (52) 718 (55) 83 (62)
Type 2 DM, n (%) 686 (17) 211 (16) 29 (22)
eGFR* (mL/min/1.73 m
2)7 6 6 18 76 6 18 73 6 19
Localisation of vascular disease, n (%):
- coronary artery disease 2449 (60) 813 (62) 86 (64)
- cerebrovascular disease 1198 (29) 365 (28) 34 (26)
- peripheral artery disease 824 (20 260 (20) 31 (23)
- aneurysm of abdominal aorta 367 (9) 119 (9) 9 (7)
Lipid-lowering medication, n (%) 2596 (63) 869 (66) 90 (67)
Antihypertensive medication, n (%) 3003 (73) 974 (74) 105 (78)
Current smoking, n (%) 1383 (34) 388 (30) 43 (32)
Current alcohol use, n (%) 1993 (49) 661 (50) 61 (46)
* Glomerular Filtration Rate, estimated by the Modification of Diet in Renal Disease (MDRD) equation.
doi:10.1371/journal.pone.0101082.t001
Figure 1. Relation between minor allele frequencies and levels
of plasma TG. Rs964184 minor allele frequency (95% confidence
interval) at increasing levels of TG. N indicates the number of patients
with a plasma TG level in this category.
doi:10.1371/journal.pone.0101082.g001
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by BMI (p for interaction=0.03, Figure 2). When stratified for
genotype, only the effect of the CG genotype was modified by BMI
(p for interaction=0.02). Including a quadratic term for BMI did
not change these results. In the patients heterozygous for the
minor allele with a BMI,24 kg/m
2, log(TG) was increased with
0.02 (95%CI 20.04 2 0.09) compared with patients without the
minor allele, whereas the log(TG) was 0.13 (95%CI 0.08–0.18)
higher in patients with a BMI$24 kg/m2 and ,27 kg/m2 and
0.17 higher (95%CI 0.12–0.22) in patients with a BMI $ 27 kg/
m2. Conversely, per 1 kg/m
2 increase in BMI, log(TG) increased
with 0.038 (95%CI 0.031–0.045) in heterozygous patients
compared with 0.028 (95%CI 0.024–0.032) and 0.030 (95%CI
0.006–0.054) in patients homozygous for the major or the minor
allele, respectively.
Relation between rs964184 and metabolic syndrome and
lipid treatment targets
The prevalence of the metabolic syndrome is higher in patients
with the minor allele. The prevalence was 52% in patients
homozygous for the major allele and 62% in patients homozygous
for the minor allele, (Odds Ratio of 1.14 (95%CI 1.03–1.27))
(Table 3). Furthermore, the elevated plasma TG levels also results
into a decreased proportion of patients who were at the nonHDL-
c or apoB treatment target (Table 3), whereas it did not influence
the proportion of patients reaching the LDL-c target of ,
2.5 mmol/L. In patients with two copies of the major allele and
using lipid-lowering medication 55% were at the nonHDL-c target
of ,3.3 mmol/L, whereas in patients with 2 copies of the minor
allele and using lipid-lowering medication, this was 47%. For the
apoB target, 80% of the patients with two copies of the major
allele were at treatment target as opposed to 67% of the patients
with two copies of the minor allele.
Table 2. Relation between rs964184 (per minor allele) and lipid levels.
Beta (95% CI) P
Log(TG) 0.12 (0.10 – 0.15) 1.1*10
219
HDL-c 20.03 (20.04 – 20.01) 0.007
NonHDL-c*: 0.14 (0.09 – 0.20) 6.3*10
27
LDL-c 0.02 (20.03 – 0.07) 0.34
ApoB* 0.03 (0.01 – 0.05) 0.004
Linear regression adjusted for age and sex.
*Additionally adjusted for lipid-lowering medication.
doi:10.1371/journal.pone.0101082.t002
Figure 2. Association between body mass index and plasma log(TG), stratified by rs964184 genotype. Black line: CC genotype, red line:
CG genotype, blue line: GG genotype. Dotted lines indicate 95% confidence interval.
doi:10.1371/journal.pone.0101082.g002
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events
During 32,200 patient-years of follow-up, a total of 825 vascular
events occurred. There was no relation between rs964184 and
occurrence of new vascular events (HR 0.99; 95%CI 0.86–1.13;
Table 4), vascular mortality (HR 1.09; 95%CI 0.92–1.30) or
myocardial infarction (HR 1.00; 95%CI 0.83–1.21). After
adjustment for plasma TG, the HRs decreased, consistent with
an association between both rs964184 and plasma TG, and
between plasma TG and vascular events.
Discussion
The SNP rs964184 in the APOA5-A4-C3-A1 region is
associated with plasma TG level in patients with clinically manifest
vascular disease. In patients with one minor allele, this association
is modified by BMI. Furthermore, rs964184 was related to the
presence of metabolic syndrome, but was not related to the risk for
new vascular events.
Previous studies have shown that several polymorphisms in or
near the APOA5-A4-C3-A1 gene complex, among which
rs964184, are associated with plasma TG level [5,7,8] and
vascular risk [10] in healthy populations. To our knowledge, no
studies have specifically addressed this issue in patients with
vascular disease. Among patients with clinically manifest vascular
disease, the metabolic syndrome and elevated TG levels are
common [14], and the results of the present study show that
rs964184 is associated with plasma TG in these patients, as well as
with HDL-c, nonHDL-c and apoB. Although in this population of
patients with manifest vascular disease the average TG levels may
be higher than in the general population, the magnitude of the
association is still similar to the association reported in the general
population [5,7,8]. Due to the higher level of TG-rich particles,
the LDL-c levels are less accurate in estimating the atherosclerotic
lipoprotein particle burden, since there is an higher concentration
of atherogenic TG-rich remnant particles and since higher TG
plasma levels lead to development of atherogenic small dense LDL
particles [17]. Therefore, the nonHDL-c levels or apoB levels may
better reflect the cardiovascular risk since they include all
atherogenic particles. This is demonstrated in the present study,
indicating a smaller chance to be at the apoB treatment target
associated with the minor allele, despite a similar proportion of
patients being at the LDL-c treatment target.
The prevalence of the metabolic syndrome in carriers of the
minor allele was higher and this finding is concordant with results
in the general population, although the relation is less strong than
in the general population [18]. This may be due to the already
higher prevalence of the metabolic syndrome among patients with
manifest vascular disease, attenuating the contrast between groups
with a different genotype. Nevertheless, the association of
rs964184 with the metabolic syndrome persists, showing that also
in this high risk population rs964184 does contribute to the
prevalence of the metabolic syndrome. Since this SNP only
selectively influences TG and HDL-c level, whereas the metabolic
syndrome is seen as a clustering of risk factors related to obesity
and insulin resistance, the contribution of rs964184 to the
prevalence of the metabolic syndrome may be regarded as
obscuring the real common basis of metabolic syndrome [18].
However, since the difference in plasma TG between patients
homozygous for the major allele and patients with one minor allele
depends on BMI, this will still lead to clustering of obesity and
plasma TG, in which obesity is the trigger for expression of
increased TG level. Furthermore, these type of interactions may
also explain why some obese patients are less vulnerable to develop
the metabolic consequences of obesity, as they may have a
favorable genetic background. This could be one of the underlying
explanations for the existence of metabolically healthy obese
patients [19]. Conversely, the TG levels for carriers of one minor
Table 3. Relation between rs964184 genotype and presence of metabolic syndrome or being not at lipid treatment target.
N (n*) OR (95% CI) P
Metabolic syndrome 5547 (2940) 1.14 (1.03 – 1.27) 0.01
Not at LDL-cholesterol target** 3432 (1696) 0.95 (0.83 – 1.08) 0.43
Not at nonHDL-cholesterol target** 3553 (1612) 1.12 (0.98 – 1.27) 0.10
Not at apoB target** 1730 (357) 1.26 (1.01 – 1.57) 0.04
Logistic regression model, adjusted for age and sex.
*Number of patients with metabolic syndrome or LDL-cholesterol/nonHDL-cholesterol/apoB not at target level.
**Only in patients using lipid lowering medication.
doi:10.1371/journal.pone.0101082.t003
Table 4. Relation between rs964184 and risk of new vascular events.
Myocardial infarction Vascular mortality All vascular events
HR (95%CI) HR (95%CI) HR (95%CI)
N (events) 5547 (434) 5547 (479) 5547 (825)
Model 1 1.00 (0.83–1.21) 1.09 (0.92–1.30) 0.99 (0.86–1.13)
Model 2 0.96 (0.79–1.16) 1.05 (0.88–1.25) 0.95 (0.83–1.09)
Hazard ratio (95% confidence interval) estimated with Cox proportional hazard models.
Model 1: adjusted for age and sex.
Model 2: Model 1 + triglyceride plasma level.
doi:10.1371/journal.pone.0101082.t004
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provided that their BMI is low. This is in line with the model that
common genetic variants combined with modifier variables (genes
or other factors such as obesity and insulin resistance) together lead
to elevations in plasma TG levels [4] and it is in accordance with
the mechanism by which also mutations in the near APOA5 gene
cause hypertriglyceridemia, requiring a second factor to express
the clinical phenotype [20]. Although genotype cannot be
changed, the phenotype may be influenced by reducing body-
weight, and our results underscore the importance of advocating
weight loss for overweight patients with hypertriglyceridemia.
Rs964184 was not associated with recurrent vascular events in
the present study. A reason for the apparent absence of the
association between rs964184 and vascular events could be the
sample size of the study, since especially patients carrying two
copies of the minor allele were infrequent and hence also few
events occurred in this group (n=134 with 20 vascular events
during follow up). The relatively small increase in risk of vascular
events of 13% associated with the presence of rs964184 in the
general population, as found in the Cardiogram GWAS, may be
too small to be relevant in high-risk patients. Patients with
clinically manifest vascular disease not having the minor allele may
have a higher burden of other risk factors leading to a first vascular
event [21]. This can also be observed from the baseline table, as
the frequency of the minor allele is increased in patients with
coronary artery disease compared to patients with cerebrovascular
disease. This may indicate that rs964184 (and hence plasma TG) is
a more important risk factor for coronary artery disease than for
cerebrovascular disease, and that patients without the minor allele
have other risk factors, predisposing more to cerebrovascular
disease.
The present results do not justify genotyping TG-associated
SNPs in clinical practice, since they do not add clinically
significant information to readily available characteristics and
the known risk profile. However, once large scale genotyping is
available at low costs, these results show that individualized
treatment or lifestyle advices could be given since the effects of
influencing secondary factors may depend on the genetic
background.
Strengths of the study are the observational cohort reflecting
clinical reality, and the extensive phenotyping of all patients
according to standardized procedures, ascertainment of vascular
events in this cohort and low proportion (,4%) lost to follow up. A
limitation of this study is the genotyping of only one TG-associated
SNP. Furthermore, the use of lipid-lowering medication during
follow up may have changed and may thus potentially influence
the associations between the SNP and plasma TG or vascular
events. However, the effect of statins on plasma TG is small and
adjustment for baseline use of lipid-lowering medication did not
influence the results. Drugs specifically targeting plasma TG, such
as fibrates, were used by very few patients (0.8%). In addition, the
group of patients homozygote for the minor allele was relatively
small (134 patients), which could in theory result in a lack of power
to detect the effect modification by BMI in this group of patients,
hence the absence of effect modification in this group may be a
false negative finding. However, as was explained above, the
absence of effect modification by BMI in this group may also be
plausible from a theoretic point of view. Finally, the results of the
present study were not replicated in an independent cohort, which
would strengthen our conclusions. However, since this study
investigates one SNP known to be associated with plasma TG and
vascular events in the general population, it is less prone to finding
spurious associations than studies in which a large number of SNPs
is investigated for new associations with disease traits.
In conclusion, rs964184 in the APOA5 region is associated with
elevated TG plasma levels and presence of the metabolic
syndrome in patients with clinically manifest vascular disease.
Although this association translated into a decreased probability to
be at apoB treatment target and a trend towards being not at
nonHDL-c treatment target, there was no relation between
rs964184 and the risk for new vascular events in these patients.
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